ATE383429T1 - Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung - Google Patents

Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung

Info

Publication number
ATE383429T1
ATE383429T1 AT97940030T AT97940030T ATE383429T1 AT E383429 T1 ATE383429 T1 AT E383429T1 AT 97940030 T AT97940030 T AT 97940030T AT 97940030 T AT97940030 T AT 97940030T AT E383429 T1 ATE383429 T1 AT E383429T1
Authority
AT
Austria
Prior art keywords
diagnostic
binding domain
therapeutic use
fusion polypeptides
polypeptides containing
Prior art date
Application number
AT97940030T
Other languages
English (en)
Inventor
Mary Digan
Philip Lake
Hermann Gram
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE383429T1 publication Critical patent/ATE383429T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97940030T 1996-07-26 1997-07-25 Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung ATE383429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26

Publications (1)

Publication Number Publication Date
ATE383429T1 true ATE383429T1 (de) 2008-01-15

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940030T ATE383429T1 (de) 1996-07-26 1997-07-25 Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung

Country Status (28)

Country Link
EP (1) EP0917581B1 (de)
JP (1) JP3681402B2 (de)
KR (1) KR100502879B1 (de)
CN (1) CN1146664C (de)
AR (1) AR008077A1 (de)
AT (1) ATE383429T1 (de)
AU (1) AU722069B2 (de)
BR (1) BR9710605A (de)
CA (1) CA2261562C (de)
CO (1) CO4650184A1 (de)
CZ (1) CZ297634B6 (de)
DE (1) DE69738452T2 (de)
ES (1) ES2300114T3 (de)
HK (1) HK1020352A1 (de)
ID (1) ID19420A (de)
IL (2) IL128094A0 (de)
MY (1) MY120425A (de)
NO (1) NO323611B1 (de)
NZ (1) NZ333908A (de)
PE (1) PE99498A1 (de)
PL (1) PL189415B1 (de)
PT (1) PT917581E (de)
RU (1) RU2209211C2 (de)
SK (1) SK7799A3 (de)
TR (1) TR199900155T2 (de)
TW (1) TW565571B (de)
WO (1) WO1998004718A1 (de)
ZA (1) ZA976666B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
EP1088084B1 (de) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EP1208194A2 (de) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Isogene arzneimittel-ziele: polymorphismen des gens der immunglobulin e rezeptor i alpha untereinheit
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
DK2401383T3 (da) * 2009-02-27 2013-12-16 Novartis Ag Fremgangsmåder til udvælgelse af eukaryote celler, som udtrykker et heterologt protein
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP3291670A1 (de) * 2015-05-04 2018-03-14 Laboratoire Français du Fractionnement et des Biotechnologies Transgene herstellung von fc-fusionsproteinen
EP3192806A1 (de) 2016-01-13 2017-07-19 Affiris AG Alpha-kette des hochaffinen ige-rezeptors (fceria)
WO2018089335A1 (en) * 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
HK1020352A1 (en) 2000-04-14
NO990328D0 (no) 1999-01-25
EP0917581A1 (de) 1999-05-26
TW565571B (en) 2003-12-11
PT917581E (pt) 2008-04-11
CN1229439A (zh) 1999-09-22
RU2209211C2 (ru) 2003-07-27
KR20000029563A (ko) 2000-05-25
BR9710605A (pt) 1999-08-17
SK7799A3 (en) 1999-07-12
KR100502879B1 (ko) 2005-07-25
CA2261562A1 (en) 1998-02-05
EP0917581B1 (de) 2008-01-09
ID19420A (id) 1998-07-09
MY120425A (en) 2005-10-31
DE69738452T2 (de) 2008-12-24
WO1998004718A1 (en) 1998-02-05
CO4650184A1 (es) 1998-09-03
NZ333908A (en) 1999-10-28
TR199900155T2 (xx) 2000-08-21
JP2000516089A (ja) 2000-12-05
IL128094A (en) 2006-08-20
AU4202597A (en) 1998-02-20
AR008077A1 (es) 1999-12-09
PL189415B1 (pl) 2005-08-31
ES2300114T3 (es) 2008-06-01
CA2261562C (en) 2011-04-05
JP3681402B2 (ja) 2005-08-10
CZ297634B6 (cs) 2007-02-21
PE99498A1 (es) 1999-01-21
CZ24699A3 (cs) 1999-04-14
IL128094A0 (en) 1999-11-30
DE69738452D1 (de) 2008-02-21
ZA976666B (en) 1999-01-25
AU722069B2 (en) 2000-07-20
PL331356A1 (en) 1999-07-05
NO990328L (no) 1999-02-19
NO323611B1 (no) 2007-06-18
CN1146664C (zh) 2004-04-21

Similar Documents

Publication Publication Date Title
ATE383429T1 (de) Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung
DE69706948D1 (de) Weichlotwerkstoff und dessen Verwendung in ein elektronisches Bauteil
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
DE69821463D1 (de) Polypropylenharzzusammensetzung und deren verwendung
DE69806925T2 (de) Ligand-aminodextran-markierungsubstanzkonjugate und deren verwendung
DE69524283D1 (de) Prozesskassette und Bilderzeugungsgerät
DE69518570D1 (de) Prozesskassette und Bilderzeugungsgerät
DE69526692T2 (de) Prozesskartusche und Bilderzeugungsgerät
DE69031783T2 (de) Bildaufzeichnungsmaterial und Bildaufzeichnungsverfahren damit
DE69526969T2 (de) Thermoplastische harzzusammensetzung und seine verwendung
DE69514495D1 (de) Festkörper-bildverstärker und röntgenuntersuchungsgerät mit einem festkörper-bildverstärker
KR900009914A (ko) 근적외선 흡광제 및 이를 이용하여 제조된 표시/기록 물질
DE59506234D1 (de) Pigmentzubereitung und deren Verwendung
DE59802439D1 (de) Spiroverbindungen und deren verwendung
DE69401392D1 (de) Polypropylen-Harzzusammensetzung und seine Verwendung
DE69632678D1 (de) Harzzusammensetzung und deren verwendung
DE69620270D1 (de) Backfett und dessen Verwendung
DE69817432D1 (de) Cycloolefinpolymere und deren Verwendung
DE69713512D1 (de) Substituierte phtalocyanine und deren verwendung
DE69519821T2 (de) Pulverförmiges Material zur Verwendung beim Wiederstandsschweissen von Aluminiumgegenständen und Wiederstandsschweissen von Aluminiumgegenständen
DE69431350T2 (de) Vergiessbares canola-öl und dessen verwendung in nahrungsmitteln
DE59504919D1 (de) Verfahren zur herstellung von ammonium-2-hydroxy-4-(methylthio)-butyrat und dieses enthaltende mischungen in flüssiger form und deren verwendung
DE69523362T2 (de) Bilderzeugungsverfahren und Prozesskassette
DE69411942D1 (de) Mehrschichtenmaterial und eine dieses material enthaltende anordnung
DE59003753D1 (de) Substituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917581

Country of ref document: EP